MEDPLUS2024-04-012024-06-30 MEDPLUS2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member MEDPLUS2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543427 MEDPLUS NOTLISTED Medplus Health Services Limited Equity 2024-04-01 2025-03-31 2024-08-02 2024-06-27 INR Millions First quarter 15:30:00 17:20:00 2024-08-02 2024-08-02 Not applicable Single segment In accordance with Ind AS 108, Operating Segments, segment information has been given in the consolidated financial statements of MedPlus Health Services Private Limited and therefore no separate disclosure on segment information is given in these standalone financial statements 2024-04-01 2024-06-30 Audited Standalone 1783260000.00 18400000.00 1801660000.00 123770000.00 1265240000.00 2140000.00 112300000.00 20990000.00 64740000.00 96390000.00 1685570000.00 116090000.00 0.00 116090000.00 28680000.00 -5150000.00 23530000.00 0.00 92560000.00 0.00 0.00 0.00 0.00 92560000.00 0.00 92560000.00 0.00 0.00 239090000.00 2 0.77 0.77 0.00 0.00 0.77 0.77 1.The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“listing regulations”) from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 02, 2024. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unmodified review report on the same. 2.During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021. The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below (Rs. In Millions) Objects as per Prospectus Planned utilisation as per Prospectus Utilisation up to June 30, 2024 Unutilised amount as on June 30, 2024* i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements 4,671.70 4,671.70 - ii) General Corporate Purposes 1,111.03 448.53 662.50 Total 5,782.73 5,120.23 662.50 * The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank. 3.As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results. 4.During the year ended March 31, 2024, with respect to the merger between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, the Company has received approval from equity shareholders and trade creditors in a meeting held on December 15, 2023 pursuant to NCLT order dated November 7, 2023. The Company has filed the final petition with the NCLT for approval under Section 232 Read with Section 230 of the Companies Act, 2013 dated December 26, 2023. The final order is awaited from NCLT. Consequent adjustments in the financial statements will be made on receipt of requisite order. 5.The standalone figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of said financial year. 6.The earnings per equity share for the quarters are not annualised. 7.During the quarter and year ended 31 March 2024, pursuant to an assessment of future profitability of the operations of the Company, the management has recognized deferred tax assets amounting to Rs. 33.59 million on unused business losses and unabsorbed depreciation of earlier years. 8.The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. For and on behalf of the Board of Directors of MedPlus Health Services Limited G.Madhukar Reddy Managing Director and Chief Executive Officer DIN: 00098097 Place: Hyderabad Date: August 02, 2024 Other Expenses 96390000.00 0.00 0.00